Product Description
Mechanisms of Action: Gene Therapy,CFH
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 4D Molecular
Company Location: EMERYVILLE CA 94608
Company CEO: David Kirn
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - 4D Molecular presented P0 Geographic Atrophy results on 2024-05-09 for 4D-175
Highest Development Phases
Phase 0: Geographic Atrophy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/10/2025 |
News Article |
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway |
|
06/24/2024 |
News Article |
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy |
|
05/01/2024 |
News Article |
4DMT Announces Presentations at ARVO 2024 Annual Meeting |
|
01/04/2024 |
News Article |
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates |